Inmune Bio Inc. claimed a phase II win with TNF inhibitor Xpro (pegipanermin) in early Alzheimer’s disease (AD), though the ...

The IPO market for med-tech companies continues to set new records. With one IPO closed the last week of June, two slated for ...